Forskning ved Københavns Universitet - Københavns Universitet

Forside

S-phase induction by interleukin-6 followed by chemotherapy in patients with refractory multiple myeloma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • P de Nully Brown
  • P O Jensen
  • Marcus Diamant
  • B T Mortensen
  • Doris Hovgaard
  • P Gimsing
  • N I Nissen
The plasma cell labeling index (PCLI) in patients with multiple myeloma (MM) is relatively low and this has been associated with the low rate of remission following chemotherapy. Interleukin-6 (IL-6) has been demonstrated to be a major growth factor of myeloma cells. In order to increase the S-phase proportion of myeloma cells, which might increase the sensitivity to chemotherapy, we gave rhIL-6 followed by chemotherapy to 15 myeloma patients with refractory disease. A total of 25 treatment cycles were administered since ten patients had two cycles. The rhIL-6 dose was 2.5 (n = 3), 5.0 (n = 6) and 10.0 microg/kg (n = 6) by subcutaneous injection once daily for 5 days and chemotherapy was administered on the last day of rhIL-6 injection. The effect of rhIL-6 treatment on labeling index (LI) was heterogeneous, but no statistically significant change was noted for this particular group as a whole. In two patients an increase (mean 7.7%) in LI of mononuclear bone marrow cells during the rhIL-6 treatment was demonstrated and in one patient a decrease of 2.8% was seen. Assessment of PCLI demonstrated an increase of 2.9% in one out of six patients and a decrease of 1.9% in one out of six patients. None of the 15 patients achieved remission according to standard criteria. During the rhIL-6 treatment, 14 of the 15 patients developed mild constitutional adverse events (AE) well known in patients treated with IL-6, and none of the AE in the subsequent chemotherapy phase were related to IL-6. In conclusion, our study demonstrated that rhIL-6 can be administered safely to patients with refractory MM, but the cell cycle recruitment approach was not sufficiently effective to be of clinical value.
OriginalsprogEngelsk
TidsskriftLeukemia Research
Vol/bind22
Udgave nummer11
Sider (fra-til)983-9
Antal sider7
ISSN0145-2126
StatusUdgivet - 1998

ID: 40155257